🇺🇸 FDA
Patent

US 11566263

Compositions and methods for treating CEP290 associated disease

granted A61KA61K35/761A61K9/0048

Quick answer

US patent 11566263 (Compositions and methods for treating CEP290 associated disease) held by Editas Medicine, Inc. expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Editas Medicine, Inc.
Grant date
Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K35/761, A61K9/0048